Description of the Product Sample Clauses

Description of the Product. Sativex® is a pump action oro-mucosal spray, which contains 2 whole plant extracts (Botanical Drug Substances, BDSs) of Cannabis sativa L. *** *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. Sativex® contains the following: Components Amount per unit (1ml) Function ***: *** *** *** *** *** *** ***: *** *** *** *** *** *** *** *** ***
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Description of the Product. Seller shall sell to Customer, and Customer shall purchase from Seller, the Product, which are unique design items made from cork material.
Sample 1
Description of the Product. 3.1 When entering into the Agreement, the Customer must choose whether the Product shall be subject to a term of between 30 and 60 days (“the Term”), when the Term shall take effect, and whether to automatically extend the Term when such a Term expires. A Term can only be extended automatically by 30 days at a time. If the Customer has chosen the automatic extension, the new Term shall start on the day following the expiry of the previous Term. If the Customer has not chosen automatic extension, the Customer may extend the Term using the Issuer’s self- service system.
Sample 1
Description of the Product. Seller shall sell to Customer, and Customer shall purchase from Seller, the Product which is a pair of gloves designed to simulate the effects and/or certain physical conditions of arthritis.
Sample 1
Description of the Product. Please note that the Results (as defined below) do not in any way constitute medical advice and Epilog NV cannot be held liable for any consequences (including any damages) resulting from a misinterpretation of the Results by the User. Within Epilog NV a software platform “Epilog” has been developed that processes electro-­‐encephalography (EEG) and magnetic resonance imaging (MRI) data uploaded by a user of the Platform. The Platform enables Users to receive an analysis of EEG data of a subject that they have uploaded as well as a 3-­‐dimensional reconstruction and visualization of this EEG data within the brain of the subject.
Sample 1
Description of the Product. 2.1. When entering into the Agreement, the Customer must choose whether the Product shall be subject to a term of between 30 and 60 days (“the Term”), when the Term shall take effect, and whether to automatically extend the Term when such a Term expires. A Term can only be extended automatically by 30 days at a time. If the Customer has chosen the automatic extension, the new Term shall start on the day following the expiry of the previous Term. If the Customer has not chosen automatic extension, the Customer may extend the Term by contacting the Issuer via email xxx@xxxxxxx.xxx or phone 00 00 00 00.
Sample 1
Description of the Product. The Product seeks a total return, before operating expenses of the Product are deducted, that replicates the total return of the Index. The Product seeks to achieve its objective primarily by investing in substantially all of the component securities included in the Index in approximately the same proportions as they are represented in the Index. However, the Product is not required to invest its assets so as to meet any specified coefficient of correlation to the Index. The Product will maintain at least 90% of its net assets in the securities that comprise the Index, except that the percentage of its assets so invested (and in any event for a period of not more than five trading days) may temporarily fall below the 90% mxxx if the Product receives cash inflows that it cannot invest immediately in securities that replicate the Index. From time to time, up to 5% of the Product's total assets may be held in cash, cash equivalents or certain short-term, fixed-income securities. These investments will not perform the same as the Index. In order to achieve performance that more closely replicates the performance of the Index, the Product may invest up to 10% of its total assets in exchange-traded index futures contracts and index options. The Product is more specifically described in the currently effective Product prospectus. EXHIBIT B License Fees LICENSEE shall pay ARCA License Fees as follows: LICENSEE shall not be obligated to pay any License Fees until the sooner to occur of: (i) the assets under management of the Product reach $60 million on any given day or (ii) 365 days after the date on which the Product commences trading on NYSE Arca. Upon the occurrence of the first of the events listed above, LICENSEE shall pay the following fees: six (6) basis points on the average daily assets under management of the Product. The License Fees shall be paid to ARCA within thirty (30) days after the close of each calendar quarter in which they are incurred; each such payment shall be accompanied by a statement setting forth the basis for its calculation.
Sample 1
AutoNDA by SimpleDocs
Description of the Product. For every patient, the system requires:
Sample 1

Related to Description of the Product

  • Product ACCEPTANCE Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User(s) shall have thirty (30) days from the date of delivery to accept hardware products and sixty (60) days from the date of delivery to accept all other Product. Where the Contractor is responsible for installation, acceptance shall be from completion of installation. Failure to provide notice of acceptance or rejection or a deficiency statement to the Contractor by the end of the period provided for under this clause constitutes acceptance by the Authorized User(s) as of the expiration of that period. The License Term shall be extended by the time periods allowed for trial use, testing and acceptance unless the Commissioner or Authorized User agrees to accept the Product at completion of trial use. Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User shall have the option to run testing on the Product prior to acceptance, such tests and data sets to be specified by User. Where using its own data or tests, Authorized User must have the tests or representative set of data available upon delivery. This demonstration will take the form of a documented installation test, capable of observation by the Authorized User, and shall be made part of the Contractor’s standard documentation. The test data shall remain accessible to the Authorized User after completion of the test. In the event that the documented installation test cannot be completed successfully within the specified acceptance period, and the Contractor or Product is responsible for the delay, Authorized User shall have the option to cancel the order in whole or in part, or to extend the testing period for an additional thirty (30) day increment. Authorized User shall notify Contractor of acceptance upon successful completion of the documented installation test. Such cancellation shall not give rise to any cause of action against the Authorized User for damages, loss of profits, expenses, or other remuneration of any kind. If the Authorized User elects to provide a deficiency statement specifying how the Product fails to meet the specifications within the testing period, Contractor shall have thirty (30) days to correct the deficiency, and the Authorized User shall have an additional sixty (60) days to evaluate the Product as provided herein. If the Product does not meet the specifications at the end of the extended testing period, Authorized User, upon prior written notice to Contractor, may then reject the Product and return all defective Product to Contractor, and Contractor shall refund any monies paid by the Authorized User to Contractor therefor. Costs and liabilities associated with a failure of the Product to perform in accordance with the functionality tests or product specifications during the acceptance period shall be borne fully by Contractor to the extent that said costs or liabilities shall not have been caused by negligent or willful acts or omissions of the Authorized User’s agents or employees. Said costs shall be limited to the amounts set forth in the Limitation of Liability Clause for any liability for costs incurred at the direction or recommendation of Contractor.

  • Packaging and Labeling Seller shall properly xxxx, xxxx, and ship Goods and provide Buyer with shipment documentation showing the Order number, Seller’s identification number for the subject Goods, the quantity of goods in shipment and the number of cartons or containers in the shipment.

  • Product Description The lead products covered by this Settlement Agreement is limited to following Amazon Identification Number (ASIN) B0BBMRLNV9, with the description, "Lesnow 63-37 Tin Lead Rosin Core Solder Wire for Electrical Soldering 0.8mm Soldering Wire Electronics Solder Content Solder Flux 1.8% (0.8mm, 50g)," which was offered for sale by the Settling Entity on xxxxxx.xxx, hereinafter the “Product” or “Products.”

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Manufacturing (a) The Supplier shall without limitation be responsible, at no additional cost to the Purchaser, for: sourcing and procuring all raw materials for the Products; obtaining all necessary approvals, permits and licenses for the manufacturing of the Products; providing sufficient qualified staff and workers to perform the obligations under this Purchase Agreement; implementing and maintaining effective inventory and production control procedures with respect to the Products; and handling other matters as reasonably requested by the Purchaser from time to time.

  • Labeling Upon request, Lessee will xxxx the Equipment indicating Lessor's interest with labels provided by Lessor. Lessee will keep all Equipment free from any other marking or labeling which might be interpreted as a claim of ownership.

  • Manufacture 2.1. The LED(s) on the LED module shall be equipped with suitable fixation elements.

  • Product Development Attach all requested documentation and attach additional pages as necessary. For all requirements include efforts of all Sublicensees. If not applicable, please so indicate by N/A.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Tests and Preclinical and Clinical Trials The studies, tests and preclinical and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder (collectively, “FFDCA”); the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the General Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company is not aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the General Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical state of development; and, except to the extent disclosed in the Registration Statement, the General Disclosure Package or the Prospectus, neither the Company nor any Subsidiary has received any notices or correspondence from the FDA or any Governmental Entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

Time is Money Join Law Insider Premium to draft better contracts faster.